Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 6.9%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shares were up 6.9% on Wednesday . The stock traded as high as $11.69 and last traded at $11.57. Approximately 131,961 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 358,216 shares. The stock had previously closed at $10.82.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets lowered their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday. Truist Financial assumed coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.29.

Y-mAbs Therapeutics Trading Up 10.6 %

The firm has a market cap of $525.28 million, a PE ratio of -23.86 and a beta of 0.66. The company’s 50-day moving average is $11.86 and its 200 day moving average is $13.73.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. The business had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. During the same quarter last year, the company earned ($0.14) EPS. On average, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Bo Kruse sold 31,371 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares of the company’s stock, valued at approximately $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 7,351 shares of the stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock valued at $1,203,925 in the last ninety days. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in YMAB. Dimensional Fund Advisors LP grew its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after buying an additional 65,732 shares during the period. Los Angeles Capital Management LLC boosted its stake in Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after acquiring an additional 52,610 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after acquiring an additional 8,974 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after acquiring an additional 3,589 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in Y-mAbs Therapeutics during the 4th quarter worth approximately $562,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.